Cargando…
P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430978/ http://dx.doi.org/10.1097/01.HS9.0000971412.45898.1a |
| _version_ | 1785091089242259456 |
|---|---|
| author | Hutchings, Martin Carlo-Stella, Carmelo Morschhauser, Franck Dickinson, Michael Bachy, Emmanuel Cartron, Guillaume Khan, Cyrus Tani, Monica Martinez-Lopez, Joaquín Bartlett, Nancy L. Salar, Antonio Brody, Joshua Leppa, Sirpa Baumlin, Pauline Lundberg, Linda Relf, James Xie, Yuying Bottos, Alessia Humphrey, Kathryn Falchi, Lorenzo |
| author_facet | Hutchings, Martin Carlo-Stella, Carmelo Morschhauser, Franck Dickinson, Michael Bachy, Emmanuel Cartron, Guillaume Khan, Cyrus Tani, Monica Martinez-Lopez, Joaquín Bartlett, Nancy L. Salar, Antonio Brody, Joshua Leppa, Sirpa Baumlin, Pauline Lundberg, Linda Relf, James Xie, Yuying Bottos, Alessia Humphrey, Kathryn Falchi, Lorenzo |
| author_sort | Hutchings, Martin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430978 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309782023-08-17 P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY Hutchings, Martin Carlo-Stella, Carmelo Morschhauser, Franck Dickinson, Michael Bachy, Emmanuel Cartron, Guillaume Khan, Cyrus Tani, Monica Martinez-Lopez, Joaquín Bartlett, Nancy L. Salar, Antonio Brody, Joshua Leppa, Sirpa Baumlin, Pauline Lundberg, Linda Relf, James Xie, Yuying Bottos, Alessia Humphrey, Kathryn Falchi, Lorenzo Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430978/ http://dx.doi.org/10.1097/01.HS9.0000971412.45898.1a Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Hutchings, Martin Carlo-Stella, Carmelo Morschhauser, Franck Dickinson, Michael Bachy, Emmanuel Cartron, Guillaume Khan, Cyrus Tani, Monica Martinez-Lopez, Joaquín Bartlett, Nancy L. Salar, Antonio Brody, Joshua Leppa, Sirpa Baumlin, Pauline Lundberg, Linda Relf, James Xie, Yuying Bottos, Alessia Humphrey, Kathryn Falchi, Lorenzo P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_full | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_fullStr | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_full_unstemmed | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_short | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_sort | p1129: glofitamab monotherapy in patients with relapsed/refractory (r/r) large b-cell lymphoma (lbcl): extended follow-up and landmark analyses from a pivotal phase ii study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430978/ http://dx.doi.org/10.1097/01.HS9.0000971412.45898.1a |
| work_keys_str_mv | AT hutchingsmartin p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT carlostellacarmelo p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT morschhauserfranck p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT dickinsonmichael p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT bachyemmanuel p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT cartronguillaume p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT khancyrus p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT tanimonica p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT martinezlopezjoaquin p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT bartlettnancyl p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT salarantonio p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT brodyjoshua p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT leppasirpa p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT baumlinpauline p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT lundberglinda p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT relfjames p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT xieyuying p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT bottosalessia p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT humphreykathryn p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT falchilorenzo p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy |